Sernova Corp. (PSH.F)
| Previous Close | 0.1769 |
| Open | 0.1701 |
| Bid | 0.1804 x 1000000 |
| Ask | 0.1926 x 1000000 |
| Day's Range | 0.1701 - 0.1850 |
| 52 Week Range | 0.1701 - 0.6405 |
| Volume | |
| Avg. Volume | 6,948 |
| Market Cap | 56.687M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Sept 12, 2024 - Sept 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Sernova Corp.
Announces developments in its Phase I/II clinical trial investigating a novel treatment for Type 1 Diabetes ...
CNW GroupSernova Announces Marketed Public Offering of Units
Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) is pleased to announce that it has filed a preliminary short form prospectus in connection with a best efforts marketed public offering (the "Offering") of units of the Company (the "Units"). The Offering is being led by Stifel Nicolaus Canada Inc., as lead agent (the "Lead Agent") and joint bookrunner with Leede Jones Gable Inc., on behalf of a syndicate of agents that includes Ventum Financial Corp., Raymond Jam
GlobeNewswireSernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hem
